MHQ: Clinical IntelligencePowered by SurvivorNet

Medical History
Clinical Trials

?

Prefer to talk instead of typing?

Answers offered are informational and do not constitute medical advice. Learn more

Medical History

Review your patient’s information.

What is your gender?

What is your age?

Clinical Trials

Clear List

Sign In

Hematologic Malignancies

ASCO 2026 and Beyond: Novel Immunotherapy Combinations Push Earlier Into B-Cell Lymphoma Treatment

Dr. Natalie Rafaeli

Bridging the Gap: Making Breakthrough Follicular Lymphoma Treatments Accessible Beyond Major Cancer Centers

SurvivorNet Staff

follicular lymphoma

NYU’s Dr. Catherine Diefenbach On Navigating the Evolving Chemo-Free Landscape in Relapsed Follicular Lymphoma

Dr. Natalie Rafaeli

follicular lymphoma

Tafasitamab Plus Lenalidomide and Rituximab in Relapsed or Refractory Follicular Lymphoma

multiple myeloma

ASCO Updates: SUCCESSOR-2 Explores a New Sequencing Strategy After Lenalidomide in Multiple Myeloma

Dr. Natalie Rafaeli

multiple myeloma

Tec-Dara vs. CAR T-Cell Therapy: Sequencing BCMA-Directed Therapy in Multiple Myeloma

Dr. Natalie Rafaeli

multiple myeloma

Epcoritamab Plus R² Demonstrates Superior Outcomes in Second-Line Follicular Lymphoma

Dr. Natalie Rafaeli

Menin Inhibitors: Interpreting Impact On Acute Myeloid Leukemia (AML) Treatment

Dr. Rodrigo C. Leão Edelmuth,

Hospital Israelita Albert Einstein

Tafasitamab Plus Lenalidomide and Rituximab in Relapsed or Refractory Follicular Lymphoma

Experimental BCMA CAR T-Cell Therapy Anito-cel Shows Deepening Responses in Relapsed/Refractory Multiple Myeloma

Dr. Natalie Rafaeli

Fixed-Duration Vs. Continuous Targeted Therapy in CLL: The CLL17 Trial Provides Much-Needed Answers

Dr. Natalie Rafaeli

Jaypirca: A Promising Therapy Against Chronic Lymphocytic Leukemia

Dr. Rodrigo C. Leão Edelmuth,

Hospital Israelita Albert Einstein

Amplify Phase III Trial: Comprehensive Overview and Clinical Significance for CLL Patients

Treatment Sequencing and Potential New Combination Options for Chronic Lymphocytic Leukemia

Integrating Venetoclax into CLL Management is Expanding Treatment Horizons and Improving Survival

Choosing Between a BTK Inhibitor & Car T-Cell Therapy

Latest Therapies For Managing Patients With Treatment-Naive CLL: Comparing Calquence, Imbruvica, and Brukinsa

Staying Connected & Sharing Knowledge: How Community Doctors Can Stay on Top of the Latest in CLL Research

For Treatment-Naïve CLL: The Risks & Benefits of Time-Limited Therapy vs. Continuous Therapy

When To Treat Chronic Lymphocytic Leukemia (CLL)?

Improving Quality of Life for Immunocompromised CLL Patients

Continuous Therapy Options For CLL: Acalabrutinib vs. Zanubrutinib

follicular lymphoma

NYU’s Dr. Catherine Diefenbach On Navigating the Evolving Chemo-Free Landscape in Relapsed Follicular Lymphoma

Dr. Natalie Rafaeli

multiple myeloma

NYU Langone’s Dr. Marc Braunstein On Decision-Making In The New Era of Multiple Myeloma Treatment

multiple myeloma

Private: MonumenTAL-3 Positions GPRC5D Targeting Earlier in Relapsed or Refractory Multiple Myeloma

Dr. Natalie Rafaeli

multiple myeloma

Dr. Sagar Lonial On A New Era For Myeloma: MajesTEC-3 and CARTITUDE-4 — Second-Line Immunotherapy Choices & The Possibility of Therapy Discontinuation

Dr. Natalie Rafaeli

multiple myeloma

A New Option for Multiple Myeloma: Belantamab Mafodotin

multiple myeloma

Sarclisa Gets FDA Approval for Newly Diagnosed Multiple Myeloma — When to Use a Four-Drug Regimen

multiple myeloma

A Potential Paradigm Shift in CAR-T: inMMyCAR Trial

SurvivorNet Staff

multiple myeloma

New FDA Approval of Daratumumab and Hyaluronidase-fihj: Quick Reactions From Dr. Robert Z. Orlowski and Dr. Sagar Lonial

Monitoring For Differentiation Syndrome

multiple myeloma

Differentiation Syndrome in the Era of Targeted Therapies for Acute Myeloid Leukemia

Differentiation syndrome (DS) has re-emerged as a clinically significant toxicity with the advent of molecularly targeted therapies in AML. Once primarily associated with APL, DS...

Dr. Natalie Rafaeli

Clinical Updates & Perspectives

ASCO 2026 and Beyond: Novel Immunotherapy Combinations Push Earlier Into B-Cell Lymphoma Treatment

Menin Inhibitors in AML: From Salvage Monotherapy to Frontline Combination Strategies

BTK Inhibitor Jaypirca is Now FDA-Approved & May Help Difficult-to-Treat Mantle Cell Lymphoma

PARADIGM Trial: Rethinking Induction Therapy in Fit Patients With AML

Rytelo Gains FDA Approval for Lower-Risk Myelodysplastic Syndrome: Reducing Need For Blood Transfusions & Improving Quality of Life

Case Western's Dr. Jorge Garcia On Practical Use of ctDNA To Make Better Treatment Decisions For Bladder Cancer Patients

'A Potential Huge Benefit For Patients' - PIVOT-006 and the Future of Intermediate-Risk NMIBC

ASC2ESCALATE Co-Author Dr. David Andorsky: Response-Guided Asciminib Strategy Deepens Early Molecular Control in CML

UH Seidman Cancer Center’s Dr. Changchun Deng: CAR T-Cell Therapy May Offer Curative Potential in Follicular Lymphoma

Leading Oncologist Rings the Alarm Bell: "We Have a Crisis in Life-Saving Access to CAR T-Cell Therapy"

ASC4FIRST: Follow-Up Study Shows Improved Efficacy & Safety With Asciminib In First-Line CML

Dr. Natalie Rafaeli

A New Era in Treating Newly Diagnosed Chronic Myeloid Leukemia: The Promise of Asciminib

New Developments In Tyrosine Kinase Inhibitor Therapy (TKI) for Chronic Myeloid Leukemia (CML)

Monitoring Patients During Oral Treatment for CML

Addressing Disparities

Treatment

Black Participation in Clinical Trials Is Imperative to Reduce Racial Disparities in Multiple Myeloma

By Kayle Waterhouse African Americans must be properly represented in clinical trials to ensure equal treatment for multiple myeloma and other cancers, top oncologists told SurvivorNet...